Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Rozpoznany zaawansowany rak, dla którego nie ma standardowego leczenia
- •Wystarczająca liczba płytek krwi (≥150)
- •Wystarczająca liczba białych krwinek (≥1)
- •Prawidłowa funkcja nerek (klirens kreatyniny ≥30 mL/min)
- •Mniej niż 5% blastów w krwi
- •Spodziewana długość życia co najmniej 3 miesiące
- •Wyzdrowienie po dużej operacji i po wcześniejszej chemioterapii
✗ Disqualifies
- •Uczulenie na lek pelabresib lub podobne leki
- •Ciąża potwierdzona testem lub karmienie piersią
- •Inne warunki medyczne, które mogą być niebezpieczne w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Candiolo, Italy
Novartis Investigative Site
Pozuelo de Alarcón, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
London, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.